Related Experiment Video

Updated: Sep 23, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW

M Kumar1, A Sarkar1

  • 1Department of Biological Sciences, Birla Institute of Technology and Science K K Birla Goa Campus, Zuarinagar, Goa 403726, India.

Experimental Oncology
|May 13, 2022
PubMed

Insights

Non-small cell lung cancer (NSCLC) treatments have advanced with targeted therapies, but survival rates remain a challenge. This review explores innovative NSCLC therapies and current treatment limitations.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Non-small cell lung cancer (NSCLC) accounts for approximately 80% of lung cancer diagnoses and causes over one million deaths globally each year.
  • Molecular alterations, such as driver mutations and gene fusions, have spurred the development of targeted therapies.
  • While targeted therapies offer advantages over traditional chemotherapy, they have not fully met expectations for improving five-year survival rates in NSCLC patients.

Purpose of the Study:

  • To review innovative therapies and treatment regimens developed for NSCLC over the past two decades.
  • To identify and discuss the current challenges and limitations in the NSCLC treatment landscape.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of therapeutic advancements and their impact on NSCLC patient outcomes.
  • Synthesis of information on diagnostic methods and treatment strategies.

Main Results:

  • Significant progress has been made in targeted therapies for NSCLC based on molecular profiling.
  • Despite therapeutic innovations, substantial challenges persist in improving long-term survival for many NSCLC patients.
  • Current diagnostic and therapeutic approaches have limitations that hinder expected survival improvements.

Conclusions:

  • Innovative therapies have shown promise in NSCLC management, but further advancements are needed.
  • Addressing the limitations in current diagnostic methods and therapeutic strategies is crucial for enhancing NSCLC patient survival.
  • Continued research into novel treatment regimens and personalized medicine approaches is essential for overcoming NSCLC challenges.

More Related Videos

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma06:11

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

Published on: April 20, 2018

9.9K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.2K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
470
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
681